Pembrolizumab for Non–Muscle-Invasive Bladder Cancer—A Costly Therapy in Search of Evidence-Reference-Cited by-同舟云学术

Pembrolizumab for Non–Muscle-Invasive Bladder Cancer—A Costly Therapy in Search of Evidence

Published:2021-04-01 Issue:4 Volume:7 Page:501
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Gill Jennifer¹,Prasad Vinay¹

Affiliation:

1. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2774444/jamaoncology_gill_2020_vp_200037_1617384999.50451.pdf

Reference7 articles.

1. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline.;Chang;J Urol,2016

2. Early vs delayed radical cystectomy for ‘high-risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival.;Jäger;BJU Int,2011

3. Economic aspects of bladder cancer: what are the benefits and costs?;Sievert;World J Urol,2009

4. Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States.;Huang;Pharmacoeconomics,2017

5. Merck. FDA approves Merck’s KEYTRUDA® (pembrolizumab) for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma In situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. Accessed January 8, 2020. https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ-with-or-without-papillary-tumors-wh/

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette–Guérin Immunotherapy of Bladder Cancer;Cells;2024-04-18

2. Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia;Frontiers in Urology;2024-02-14

3. Identification of m6A suppressor EIF4A3 as a novel cancer prognostic and immunotherapy biomarker through bladder cancer clinical data validation and pan-cancer analysis;Scientific Reports;2023-09-30

4. Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity;European Journal of Cancer;2023-07

5. Management of Non-Muscle Invasive Bladder Cancer;A Guide to Management of Urological Cancers;2023